{"id":"proventil-hfa","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nervousness"},{"rate":"1-3","effect":"Palpitations"},{"rate":"1-3","effect":"Muscle cramps"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":{"setId":"f454947c-6055-474b-bf35-29a379e01aa3","title":"PROVENTIL HFA (ALBUTEROL SULFATE) AEROSOL, METERED [MERCK SHARP & DOHME CORP.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug binds to beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP levels. This leads to smooth muscle relaxation and bronchodilation, providing rapid symptom relief during acute asthma attacks or exercise-induced bronchoconstriction. The HFA formulation uses hydrofluoroalkane propellant instead of chlorofluorocarbon.","oneSentence":"Proventil HFA is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:41.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm relief in asthma"},{"name":"Prevention of exercise-induced bronchoconstriction"},{"name":"Maintenance treatment of asthma"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT01931696","phase":"NA","title":"Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-08","conditions":"Asthma","enrollment":200},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT00739297","phase":"PHASE1","title":"The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-07","conditions":"Chronic Asthma","enrollment":68},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02126839","phase":"PHASE3","title":"A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05","conditions":"Asthma","enrollment":186},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT03528577","phase":"PHASE3","title":"A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-09-22","conditions":"Asthma","enrollment":128},{"nctId":"NCT00557180","phase":"","title":"Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2007-10","conditions":"Asthma, Obesity","enrollment":33},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT00394329","phase":"PHASE3","title":"(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-11","conditions":"Asthma","enrollment":288},{"nctId":"NCT03549897","phase":"PHASE3","title":"Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-03-16","conditions":"Asthma","enrollment":100},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT00528723","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT01344655","phase":"PHASE4","title":"Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT00400608","phase":"PHASE4","title":"A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Asthma","enrollment":28},{"nctId":"NCT02150499","phase":"PHASE3","title":"A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":18},{"nctId":"NCT01019694","phase":"PHASE3","title":"Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":470},{"nctId":"NCT02173678","phase":"PHASE1","title":"Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01844401","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-04","conditions":"Asthma","enrollment":15},{"nctId":"NCT00096616","phase":"PHASE2","title":"Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Asthma","enrollment":113},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT00583986","phase":"PHASE3","title":"Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-09","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, COPD","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["albuterol sulfate"],"phase":"marketed","status":"active","brandName":"Proventil® HFA","genericName":"Proventil® HFA","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Proventil HFA is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow. Used for Acute bronchospasm relief in asthma, Prevention of exercise-induced bronchoconstriction, Maintenance treatment of asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}